RepliCel Life Sciences Inc. (REPCF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 352.26 Thousand CAD | -0.42% |
| 2022 | 353.73 Thousand CAD | 0.0% |
| 2021 | 353.73 Thousand CAD | 0.0% |
| 2020 | 353.73 Thousand CAD | 0.0% |
| 2019 | 353.73 Thousand CAD | 192.07% |
| 2018 | 121.11 Thousand CAD | 3014.9% |
| 2017 | -4155.00 CAD | 28.11% |
| 2016 | -5780.00 CAD | 17.13% |
| 2015 | -6975.00 CAD | 0.0% |
| 2014 | - CAD | -100.0% |
| 2013 | 4.12 Million CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 100.0% |
| 2010 | -367.76 Thousand CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| 2008 | - CAD | 0.0% |
| 2007 | - CAD | 0.0% |
| 2006 | - CAD | 0.0% |
| 2005 | - CAD | 0.0% |
| 2004 | - CAD | 0.0% |
| 2003 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 88.29 Thousand CAD | 0.15% |
| 2024 Q2 | 88.29 Thousand CAD | 0.0% |
| 2023 Q3 | 88.43 Thousand CAD | 1.26% |
| 2023 Q1 | 88.33 Thousand CAD | -0.11% |
| 2023 FY | 352.26 Thousand CAD | -0.42% |
| 2023 Q2 | 87.33 Thousand CAD | -1.14% |
| 2023 Q4 | 88.16 Thousand CAD | -0.31% |
| 2022 Q2 | 88.43 Thousand CAD | 0.0% |
| 2022 FY | 353.73 Thousand CAD | 0.0% |
| 2022 Q1 | 88.43 Thousand CAD | 0.0% |
| 2022 Q4 | 88.43 Thousand CAD | -0.0% |
| 2022 Q3 | 88.43 Thousand CAD | 0.0% |
| 2021 Q1 | 88.43 Thousand CAD | 0.0% |
| 2021 Q3 | 88.43 Thousand CAD | 0.0% |
| 2021 Q4 | 88.43 Thousand CAD | -0.0% |
| 2021 Q2 | 88.43 Thousand CAD | 0.0% |
| 2021 FY | 353.73 Thousand CAD | 0.0% |
| 2020 Q4 | 88.43 Thousand CAD | 0.0% |
| 2020 Q2 | 63.15 Thousand CAD | 0.0% |
| 2020 Q1 | 63.15 Thousand CAD | 0.0% |
| 2020 FY | 353.73 Thousand CAD | 0.0% |
| 2020 Q3 | 88.43 Thousand CAD | 40.03% |
| 2019 Q3 | 63.15 Thousand CAD | -0.0% |
| 2019 Q2 | 63.15 Thousand CAD | 0.0% |
| 2019 FY | 353.73 Thousand CAD | 192.07% |
| 2019 Q4 | 63.15 Thousand CAD | 0.0% |
| 2019 Q1 | 63.15 Thousand CAD | -47.86% |
| 2018 FY | 121.11 Thousand CAD | 3014.9% |
| 2018 Q2 | - CAD | 0.0% |
| 2018 Q1 | - CAD | 0.0% |
| 2018 Q4 | 121.11 Thousand CAD | 0.0% |
| 2018 Q3 | - CAD | 0.0% |
| 2017 Q4 | - CAD | 0.0% |
| 2017 Q3 | - CAD | 0.0% |
| 2017 Q2 | - CAD | 0.0% |
| 2017 Q1 | - CAD | 0.0% |
| 2017 FY | -4155.00 CAD | 28.11% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2016 FY | -5780.00 CAD | 17.13% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2015 FY | -6975.00 CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 FY | - CAD | -100.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2013 FY | 4.12 Million CAD | 0.0% |
| 2013 Q4 | - CAD | -100.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q3 | 4.12 Million CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2012 Q1 | - CAD | -100.0% |
| 2012 Q2 | 1.74 Million CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q3 | - CAD | -100.0% |
| 2012 FY | - CAD | 0.0% |
| 2011 Q3 | 847.27 Thousand CAD | 755.79% |
| 2011 Q1 | -182.58 Thousand CAD | 56.79% |
| 2011 Q2 | -129.2 Thousand CAD | 29.24% |
| 2011 Q4 | 1.76 Million CAD | 108.3% |
| 2011 FY | - CAD | 100.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2010 Q4 | -422.58 Thousand CAD | 0.0% |
| 2010 FY | -367.76 Thousand CAD | 0.0% |
| 2009 Q3 | -17.49 Thousand CAD | 56.35% |
| 2009 Q4 | - CAD | 100.0% |
| 2009 Q2 | -40.08 Thousand CAD | 0.0% |
| 2009 Q1 | - CAD | 100.0% |
| 2009 FY | - CAD | 0.0% |
| 2008 Q1 | - CAD | 0.0% |
| 2008 Q4 | -38.7 Thousand CAD | 0.0% |
| 2008 Q3 | - CAD | 100.0% |
| 2008 Q2 | -25.45 Thousand CAD | 0.0% |
| 2008 FY | - CAD | 0.0% |
| 2007 Q3 | -5000.00 CAD | 0.0% |
| 2007 Q1 | - CAD | 0.0% |
| 2007 FY | - CAD | 0.0% |
| 2007 Q4 | - CAD | 100.0% |
| 2007 Q2 | - CAD | 0.0% |
| 2006 Q3 | - CAD | 0.0% |
| 2006 Q1 | - CAD | 0.0% |
| 2006 FY | - CAD | 0.0% |
| 2006 Q4 | - CAD | 0.0% |
| 2006 Q2 | - CAD | 0.0% |
| 2005 Q3 | - CAD | 0.0% |
| 2005 FY | - CAD | 0.0% |
| 2005 Q2 | - CAD | 0.0% |
| 2005 Q1 | - CAD | 0.0% |
| 2005 Q4 | - CAD | 0.0% |
| 2004 Q1 | - CAD | 0.0% |
| 2004 Q2 | - CAD | 0.0% |
| 2004 Q4 | - CAD | 0.0% |
| 2004 FY | - CAD | 0.0% |
| 2004 Q3 | - CAD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 FY | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.704% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 210.252% |
| Qrons Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -99.515% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 96.991% |
| BioStem Technologies, Inc. | 15.42 Million USD | 97.716% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 383.51% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 829.945% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.995% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 101.365% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 96.335% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -150.722% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 14542.968% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 97.651% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -11256.028% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 96.403% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -435.942% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 1131.52% |
| Mesoblast Limited | -35.16 Million USD | 101.002% |
| Marizyme, Inc. | 457.7 Thousand USD | 23.036% |
| Genus plc | 178.7 Million USD | 99.803% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.84% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -466.104% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 14.117% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 3302.4% |
| ContraFect Corporation | -154 Thousand USD | 328.743% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 804.528% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -358.91% |
| IMV Inc. | -962.29 Thousand USD | 136.607% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 190.907% |
| MultiCell Technologies, Inc. | 49.32 USD | -714141.687% |
| ONE Bio Corp. | 20.12 Million USD | 98.25% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 99.125% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -620.376% |
| Q BioMed Inc. | -8988.00 USD | 4019.27% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 98.753% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 2383.869% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.206% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 130.858% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -403.234% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 7213.57% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 461.241% |
| GB Sciences, Inc. | -624.00 USD | 56552.564% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 509.476% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 169457.692% |
| Enzolytics Inc. | 30.7 Thousand USD | -1047.141% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 26.982% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.968% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 168.466% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 42.942% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.914% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 4077.687% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 520.117% |
| Kadimastem Ltd | -630.13 Thousand USD | 155.903% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 64.345% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 3076.46% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -99.515% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 74.044% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 1314.703% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 21.727% |
| SYBLEU INC | 11.69 Thousand USD | -2911.833% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 92.355% |
| Bioxytran, Inc. | -8285.00 USD | 4351.829% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 194.441% |
| Neutra Corp. | 14.33 Thousand USD | -2357.37% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 529.59% |
| PureTech Health plc | -1.6 Million USD | 121.975% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 135.183% |
| IXICO plc | 3.27 Million USD | 89.227% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 150.759% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 119.669% |
| CSL Limited | 7.7 Billion USD | 99.995% |
| Cellectis S.A. | 18 Thousand USD | -1857.022% |